Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

13 Dec 2010

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Xeloda may reduce recurrence of faster growing breast cancers: Study

Joyce O'Shaughnessy, M.D., medical director and co-chair of the Breast Cancer Research Committee, US Oncology Research, and medical oncologist with Texas Oncology-Baylor Sammons Cancer Center, presented her study findings today at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer

13 Dec 2010

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer, announced that today a poster highlighting positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer is being presented by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine at the AACR Breast Cancer Symposium in San Antonio, TX.

13 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients - those with estrogen receptor (ER)-positive/HER2-negative disease.

10 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Cell Therapeutics announces new pixantrone EOS follow up results

Cell Therapeutics, Inc. today announced new pixantrone end of study follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application currently under review by the European Medicines Agency.

6 Dec 2010

Research reveals new standard treatment options for various forms of lymphoma

The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

New standard treatment for early stage breast cancer

Spanish Oncology has established a new standard treatment for Breast Cancer at early stages thanks to the results of the study 9805/Target 0 funded by Spanish Breast Cancer Research Group and sponsored by Sanofi Aventis.

4 Dec 2010

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

3 Dec 2010

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Cell Therapeutics, Inc. announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present end of study results for the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma at the 52nd Annual Meeting of the American Society of Hematology on Sunday, December 5, 2010 in Orlando, Florida.

1 Dec 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the "Electrochemotherapy 1st International Users' Meeting"(Bologna, Italy, November 19-20, 2010).

23 Nov 2010

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Apricus Biosciences, Inc., today announced that it has filed the protocol for a proposed Phase 3 clinical trial of PrevOnco, its proprietary treatment for hepatocellular carcinoma (liver cancer), with the U.S. Food and Drug Administration (FDA).

23 Nov 2010

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

20 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Doxorubicin News and Research

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Syndax reports promising results from entinostat preclinical studies in breast cancer

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

Xeloda may reduce recurrence of faster growing breast cancers: Study

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Obesity is associated with worse outcomes in patients with ER-positive/HER2-negative disease

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Cell Therapeutics announces new pixantrone EOS follow up results

Research reveals new standard treatment options for various forms of lymphoma

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

New standard treatment for early stage breast cancer

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News